Research12 min readAugust 8, 2026

Semaglutide vs Tirzepatide: What the Head-to-Head Trial Actually Found

For years this comparison was guesswork across separate trials with different populations. SURMOUNT-5 finally ran them against each other — 751 adults, 72 weeks, maximum tolerated doses. Tirzepatide won on weight, and that is not the whole answer.

By Med Consumer Watch Team

For most of the time these drugs have existed, comparing them meant comparing separate trials with different participants, different designs and different endpoints — which is not a comparison at all. People did it anyway, because the question is obvious and everyone wanted an answer. SURMOUNT-5 finally ran them against each other. It is a Phase 3b, open-label, randomised trial — the first published head-to-head of tirzepatide against semaglutide for weight loss in adults with obesity and without diabetes. 751 participants, 72 weeks, each drug titrated to its maximum tolerated dose. Published in the New England Journal of Medicine. The result: Tirzepatide: −22.8 kg. Semaglutide: −15.0 kg. Waist circumference followed the same pattern: −18.4 cm against −13.0 cm. Participants on tirzepatide were significantly more likely to reach every weight-loss threshold measured — at least 10%, 15%, 20% and 25%. That is a clear result and it deserves to be stated plainly rather than hedged into meaninglessness. On average weight lost, tirzepatide beat semaglutide, and it was not close. It is also not the only thing that should decide what you take — and the rest of this page is why.

Why Tirzepatide Wins on Weight: Two Receptors, Not One

The mechanistic difference is straightforward and it explains the trial result. Semaglutide (Wegovy, Ozempic, Rybelsus) is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, an incretin hormone your gut releases after eating. That slows gastric emptying, increases insulin secretion when glucose is high, and acts on appetite centres in the brain. Tirzepatide (Zepbound, Mounjaro) is a dual GIP and GLP-1 receptor agonist. It does everything semaglutide does, and also activates the GIP receptor — a second incretin pathway. The two together appear to produce a larger effect on appetite and energy balance than GLP-1 alone. That is the whole story of the trial result: one hormone pathway versus two.

Feature | Semaglutide | Tirzepatide
Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist
Weight-loss brand | Wegovy | Zepbound
Diabetes brand | Ozempic (injectable), Rybelsus (oral) | Mounjaro
SURMOUNT-5 weight change | −15.0 kg | −22.8 kg
SURMOUNT-5 waist change | −13.0 cm | −18.4 cm
Dosing in the trial | 1.7–2.4 mg, max tolerated | 10–15 mg, max tolerated
Administration | Weekly injection (oral tablet also exists) | Weekly injection

Do not read −22.8 kg as a personal forecast. That is a trial average across 751 people, and individual response varies enormously in both directions. Trial populations are also screened, supported and monitored in ways ordinary care is not. Real-world results are typically more modest than trial results for both drugs.

Note what the trial compared: maximum tolerated doses over 72 weeks. That is the fairest possible test and also the most demanding one. If you cannot tolerate titrating to a high dose — and a meaningful number of people cannot, because of gastrointestinal side effects — the gap between the two drugs at the dose you can actually stay on may be considerably smaller than the headline figures suggest.

Where Semaglutide Still Has the Advantage

A single trial endpoint does not make one drug simply better than another. Several things run the other way. Cardiovascular outcome evidence. Semaglutide has the longer and deeper record in cardiovascular outcomes trials. For someone whose primary concern is cardiovascular risk rather than the number on the scale, that history matters — and it is the kind of evidence that takes years to accumulate and cannot be inferred from a weight endpoint. An oral option exists. Semaglutide is available as a tablet (Rybelsus, and a Wegovy pill formulation). Tirzepatide is injection-only. For someone with a genuine needle phobia, that is not a minor preference — it is the difference between taking the medication and not. Longer real-world track record. Semaglutide has been in wide use longer, which means more accumulated experience with side effects, interactions and long-term management. Availability and price. In practice this often decides it. Our cost comparison covers this in detail, but compounded semaglutide is generally the cheaper of the two, and insurance formularies frequently cover one and not the other. And tolerability is individual. Both drugs share the same side-effect profile — nausea, vomiting, diarrhoea, constipation, abdominal pain, most pronounced during titration. Neither is reliably gentler. Some people tolerate one and not the other, and there is no way to know in advance which.

Both drugs carry the same boxed warning regarding thyroid C-cell tumours observed in rodent studies. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both require caution in people with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease or diabetic retinopathy. This is a conversation with a clinician who knows your history, not a choice to make from a comparison table.

There is a practical asymmetry worth knowing: because tirzepatide produces greater average weight loss, it also tends to produce faster weight loss, and rapid loss is associated with a higher risk of gallstones and greater loss of lean mass. That is an argument for adequate protein intake and resistance training on either drug, and a reason not to assume that faster is automatically better for you.

What the Trial Did Not Answer

SURMOUNT-5 is a strong trial and it has boundaries. An honest reading includes them. It excluded people with diabetes. Participants were adults with obesity without type 2 diabetes. In people with diabetes, weight-loss responses to both drugs are typically smaller, and the comparison may differ. It was open-label. Participants and investigators knew which drug they were receiving. That is normal for a trial comparing two injectables with different titration schedules, but it introduces the possibility of expectation effects in a subjective-behaviour-influenced outcome like weight. It ran 72 weeks. That is a substantial period and it is not a lifetime. These are chronic treatments for a chronic condition; what happens over five and ten years — on efficacy, on tolerability, on adherence — is not something a 72-week trial can tell you. It compared averages, not individuals. A significant difference in group means does not mean tirzepatide is better for you specifically. Some people in that trial lost more on semaglutide than the tirzepatide average. And it says nothing about compounded versions. SURMOUNT-5 tested the manufacturers' FDA-approved products. As we set out in our guide to brand-name versus compounded GLP-1s, a compounded preparation is not the drug that was studied — it is not FDA-approved, not reviewed for manufacturing quality, and not demonstrated to be therapeutically equivalent.

That last point is the one most likely to be glossed over in marketing. If a telehealth provider cites SURMOUNT-5 or the SURMOUNT and STEP trial results while selling you a compounded preparation, understand that the evidence being quoted was generated using a different product than the one being sold to you.

How to Actually Choose

In practice, the decision is usually made by four things in this order — and clinical superiority is rarely the first of them. 1. What your insurance covers. This decides it for most people. Formularies frequently cover one and not the other, and the out-of-pocket difference between covered and uncovered dwarfs the difference between the drugs. 2. What your clinician judges appropriate for your history. Prior pancreatitis, gallbladder disease, retinopathy, thyroid history, other medications, and how much weight loss is clinically indicated all shape this. 3. What you can tolerate. The best drug is the one you can stay on. If tirzepatide's titration makes you too nauseated to function and semaglutide does not, semaglutide is the better drug for you regardless of what any trial average says. 4. Cost, if you are paying cash. See our cost comparison and our cheapest programs guide. If all four are equal — which is uncommon — the trial evidence favours tirzepatide for weight loss.

Lean tirzepatide if: maximum weight loss is the goal, you tolerate titration well, and it is covered or affordable
Lean semaglutide if: cardiovascular risk reduction is a primary goal, you need an oral option, you tolerate it better, or it is the one your plan covers
Either is reasonable if: you simply need to start, because the drug you actually take beats the theoretically superior one you cannot access or tolerate
Neither, yet, if: you have not discussed contraindications with a clinician who has your full history

Switching between them is possible and reasonably common, but doses are not interchangeable — 2.4 mg of semaglutide does not map onto any particular dose of tirzepatide, and switching usually means re-titrating from a low dose. That is a prescriber's decision, not a self-managed one. If your current drug is not working or not tolerable, raise switching at a visit rather than sourcing an alternative independently.

Frequently Asked Questions

Is tirzepatide better than semaglutide? For weight loss specifically, the head-to-head evidence says yes. SURMOUNT-5 found −22.8 kg on tirzepatide against −15.0 kg on semaglutide over 72 weeks at maximum tolerated doses, with tirzepatide significantly more likely to reach every threshold measured. "Better for weight loss" is not the same as "better for you." What is the actual difference between them? Semaglutide activates one incretin receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). That second pathway is the most likely explanation for the larger effect. Which brands are which? Semaglutide: Wegovy (weight loss), Ozempic (type 2 diabetes), Rybelsus (oral). Tirzepatide: Zepbound (weight loss), Mounjaro (type 2 diabetes). Is one safer than the other? Neither is established as safer. Both share the same side-effect profile — nausea, vomiting, diarrhoea, constipation, abdominal pain — and the same boxed warning about thyroid C-cell tumours seen in rodents. Both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Which has less nausea? Neither reliably. Tolerability is individual, and some people do well on one and poorly on the other. There is no way to predict which in advance. Can I get either as a pill? Semaglutide yes — Rybelsus, and a Wegovy pill formulation. Tirzepatide is injection-only. Does SURMOUNT-5 apply to compounded versions? No. The trial tested FDA-approved manufacturer products. A compounded preparation is not FDA-approved, not reviewed for manufacturing quality, and not shown to be therapeutically equivalent. See our brand-name versus compounded guide. Can I switch from one to the other? Yes, and it is fairly common — but doses do not map across, and switching normally means re-titrating from a low dose. That is a prescriber's decision. Which is cheaper? Usually semaglutide, particularly compounded. See our cost comparison and cheapest programs guide. Does either work without diet and exercise? Both trials paired medication with lifestyle intervention. Rapid weight loss also costs lean mass, which is an argument for adequate protein and resistance training on either drug.

The Bottom Line

The head-to-head question finally has a head-to-head answer. SURMOUNT-5 — 751 adults with obesity and without diabetes, 72 weeks, both drugs at maximum tolerated dose, published in the New England Journal of Medicine — found tirzepatide produced −22.8 kg against semaglutide's −15.0 kg, with a larger waist reduction and a significantly higher chance of reaching every weight-loss threshold measured. For weight loss, that is a clear win for tirzepatide, and the mechanism explains it: two incretin receptors rather than one. It is still not the whole decision. Semaglutide has the deeper cardiovascular outcomes record, exists in an oral form for people who cannot face an injection, has a longer real-world track record, and is usually cheaper. Both carry the same boxed warning and the same contraindications. Tolerability is individual and unpredictable — and the best drug is the one you can actually stay on, which no trial average can tell you in advance. In practice the choice is usually made before clinical superiority enters it: by what your insurance covers, what your history permits, what your gut tolerates, and what you can afford. If all four genuinely come out level, the evidence points to tirzepatide. One caution that applies to most readers of this page. SURMOUNT-5 tested the manufacturers' approved products. If a telehealth provider quotes these results while selling you a compounded preparation, the evidence being cited was not generated with the product being sold. That distinction is covered in our brand-name versus compounded guide, and it is worth understanding before you buy. We are not healthcare professionals and this is not medical advice. Both semaglutide and tirzepatide carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Do not start, stop or switch any prescription medication based on a review — that is a decision for your prescribing clinician, who knows your full history. Individual results vary substantially from trial averages. This is an affiliate marketing website; see our [disclosure](/disclosure).

Sources & References

Medical Disclaimer

This article is for informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making decisions about your health or medications. Individual experiences may vary.

Tirzepatide vs Semaglutide: Cost Compared

Brand-Name vs Compounded GLP-1: What Changed in 2025

Cheapest GLP-1 Programs: What the Advertised Price Actually Buys

Back to All Articles

Enter to Win a $1,788 CoreAge Rx Gift Card

Enter for a chance to use it toward eligible CoreAge Rx products and services.

The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.